Study on ACP-196 for Treating Recurrent Glioblastoma Multiforme (GBM)

Inclusion Criteria

• Adults aged 18 or older.
• Diagnosed with glioblastoma multiforme (GBM) that has returned after initial treatments, including chemotherapy or radiotherapy with temozolomide.
• Evidence of cancer progression on an MRI scan after previous treatment.
• Have a measurable tumor of at least 1 cm in size on an MRI scan done within 21 days before starting the study drug.
• Stable or decreasing dose of steroids for at least 5 days before the baseline MRI.
• On a stable dose of any necessary medications, such as anticonvulsants, for at least 3 weeks before starting the study drug.
• Able to perform daily activities with an ECOG performance status of 0 to 2.
• Expected to live at least 12 more weeks.
• Completed all previous cancer treatments before starting the study drug.
• Recovered from any side effects of previous cancer treatments, except for mild neuropathy or hair loss.

Exclusion Criteria

• Have had three or more previous treatments for GBM.
• Have another type of cancer, unless it was a non-serious skin cancer or cervical cancer that has been treated and disease-free for at least 2 years.
• Have significant heart disease.
• Have digestive issues that affect how the body absorbs medication, such as certain bowel diseases or surgeries.
• Have a bleeding disorder.
• Need urgent treatment for the primary disease.
• Need treatment with a strong CYP3A4 inhibitor.
• Have had a stroke or significant brain bleeding in the last 6 months.
• Are pregnant or breastfeeding.
• Have been treated with bevacizumab (Avastin) before.